KLDO - Dosing underway for Kaleido Biosciences's KB295 ulcerative colitis study

Kaleido Biosciences (KLDO) -1.2% in premarket has dosed the first patient in a clinical study evaluating KB295, a Microbiome Metabolic Therapy candidate, for the treatment of ulcerative colitis ((UC)), an inflammatory bowel disease characterized by long-lasting inflammation and ulcers in digestive tract, including abdominal pain, bowel urgency and diarrhea.The 30-subject non IND/non CTA open label study will assess  the safety and tolerability of KB295. Other assessments include clinical colitis activity score, changes in microbiome composition and biomarkers of inflammation. Patients will receive KB295 for eight weeks titrated up to 40 g twice daily and then enter a one-month follow-up period.Top-line data from the study expected in mid-2021.

For further details see:

Dosing underway for Kaleido Biosciences's KB295 ulcerative colitis study